Abstract
Chemotherapy-induced peripheral neuropathy (CIPN) is an adverse event of nab-paclitaxel. The aim of this retrospective study was to assess safety and effectiveness of mirogabalin for CIPN induced by nab-paclitaxel in patients with advanced pancreatic cancer (PC).
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
